Healthcare / BiotechnologyNYSE American
$0.55
+0.03 (+6.54%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-2.9M · quality 48.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
10/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$60M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-93.9%
↓Gross Margin
-1225.0%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-13.8%
FCF CAGR
—
FCF margin
-5906.3%
FCF / Net income
0.16x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $32000.0 · net income $-11.8M · FCF $-1.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $32000.00 | $32000.00 | — | — | $50000.00 |
| Net Income | $-11.8M | $-11.8M | $-24.7M | $-4.3M | $-7.1M |
| EBITDA | $-12.5M | $-12.5M | $-22.6M | $-2.8M | $-6.3M |
| EPS | — | — | -2.30 | -0.07 | -0.61 |
| Gross Margin | -1225.0% | -1225.0% | — | — | — |
| Operating Margin | -13343.8% | -13343.8% | — | — | -6808.0% |
| Net Margin | -36993.8% | -36993.8% | — | — | -14102.0% |
| Balance Sheet | |||||
| Debt/Equity | — | — | 2.08 | 0.48 | 0.34 |
| Current Ratio | 0.22 | 0.22 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.9M | $-1.9M | $-2.9M | $-2.9M | $-2.5M |
| Returns | |||||
| ROE | -93.9% | -93.9% | -580.1% | -17.2% | -23.9% |
| Valuation | |||||
| P/B | 4.60 | 4.60 | 4.37 | — | — |
| Growth & Yield | |||||
| EPS Growth | — | — | -3185.7% | 88.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+7.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.30 → n/d
Residual
+7.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.